Baxter International Inc

Discover why Baxter’s Q4 2025 loss hit $1.2 bn, how a Midwest plant outage and cost hikes drove the dip, and what 2026 guidance means for suppliers and patients.

Discover why Baxter International’s Q4 loss hit investors hard—learn about its new operating model, cautious outlook, and what this means for the life‑science sector.

Analyze Baxter’s Q4 2025 earnings: a $0.8 B loss and $1.04‑adjusted‑EPS due to a hurricane‑damaged Gulf Coast plant, 24 % share drop, and management’s recovery plan.

Discover why Baxter International cut its dividend, the impact of reimbursement pressure, and whether its low valuation offers a buying chance for value investors.

Discover Baxter’s Dynamo Series smart stretchers—sensor‑enabled, faster deployment and real‑time telemetry that cut pressure‑ulcer and fall risks while boosting workflow efficiency.

Explore Baxter International’s market performance, product strengths, regulatory compliance, and strategic impact on healthcare costs and supply‑chain resilience.

Discover how Baxter International’s keynote at the J.P. Morgan 2026 Healthcare Conference highlights its push into connected medical devices, digital solutions, and strategic growth in a transforming healthcare market.

Explore Baxter International’s Q1 earnings: EPS beats, 3.8% revenue growth, and a deep dive into supply‑chain risks, CMS reimbursement shifts, and digital‑health investment plans.

Class‑action lawsuit hits Baxter International: discover how legal risk shakes share prices, contract leverage, and future product launches.

Explore Baxter International’s breakthrough smart‑pump study with 64% fewer medication errors, its impact on staff workload, and the latest class‑action lawsuit updates for investors and clinicians.